NeoGenomics (NASDAQ: NEO) reported Q1 EPS of $0.07, $0.03 better than the analyst estimate of $0.04. Revenue for the quarter came in at $95.6 million versus the consensus estimate of $90.61 million.

GUIDANCE:

NeoGenomics sees FY2019 revenue of $384-400 million, versus the consensus of $385 million.

For earnings history and earnings-related data on NeoGenomics (NEO) click here.